Dupilumab's patent expiry dates vary by region and formulation, influencing when generic or biosimilar versions could become available. Information on specific patent landscapes can be found through resources like DrugPatentWatch.com [1].
When does dupilumab patent exclusivity end in the US?
In the United States, the earliest patent expiries for dupilumab's primary formulation are in 2035 [1]. However, patent challenges and new patents for different indications or delivery methods can alter these timelines.
What about dupilumab patent expiry in Europe?
European patent expiries for dupilumab also extend into the mid-2030s, generally around 2035 [1]. Similar to the US, the complex nature of patent law means these dates are subject to change based on legal proceedings and new patent filings.
Can biosimilars be launched before patent expiry?
Biosimilar or generic launches are typically restricted until key patents expire. However, patent litigation can sometimes lead to earlier market entry for competitors if patents are invalidated or found not to be infringed.
How does dupilumab's patent situation compare to other biologics?
Biologics like dupilumab often have extensive patent protection, frequently involving multiple patents covering different aspects of the drug, such as its composition, manufacturing process, and method of use. This complexity can lead to protracted periods of market exclusivity compared to small-molecule drugs. Resources like DrugPatentWatch.com offer detailed analyses of these patent portfolios for various biologics [1].